pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ZURAZura Bio Ltd

$ZURA5.6400-0.88%
La Jolla, CA, USupdated 3mo ago
SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 2: 1
1Phase 2
Phase 2
tibulizumab
Hidradenitis Suppurativa
Interleukin-17ATumor necrosis factor ligand superfamily member 13B

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)active not recruitingn=80
  • phase2Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defenseactive not recruitingn=225
🐶 Hiring Signal
No open roles indexed yet — view Zura Bio Ltd jobs →

News

  • AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
    The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.
    biopharma_dive · 5d ago
  • STAT+: Gene therapy’s long-debated cancer risk materializes
    For years, gene therapy researchers debated whether the viruses they use to ferry replacement genes into cells could cause tumors. A small number of cases now offer strong evidence that…
    stat · 7d ago
  • Zura reports Phase 2 flop in painful skin disorder, stock nosedives
    A small biotech’s stock collapsed after the company reported a Phase 2 failure in a debilitating skin condition. Zura Bio said Monday morning that both doses of its experimental drug tibulizumab fa…
    endpoints · 7d ago
  • Zura scraps hidradenitis suppurativa program after phase 2 miss, sinking stock
    Zura Bio’s tibulizumab has flunked a phase 2 hidradenitis suppurativa trial, prompting the biotech to end development in the indication while continuing studies in other settings.
    fiercebiotech · 8d ago
  • JATT mastermind launches latest biotech-focused SPAC via $60M IPO
    Just two months after Someit Sidhu, M.D., succeeded in pairing off his second special purpose acquisition company (SPAC) with Talawar Therapeutics, the biotech entrepreneur is back at it again.
    fiercebiotech · 2mo ago
identifiers
ticker
$ZURA
SEC CIK
0001855644
country
US
source
sec_tickers
top tags
Dermatology1Immunology1
mentioned in
5news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 52m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?